Syntis Bio raised an additional $5 million to continue developing late-stage preclinical oral therapies that leverage intestinal biology to treat metabolic and rare diseases through daily, nutrient-blocking formulations.
Syntis Bio raised an additional $5 million to continue developing late-stage preclinical oral therapies that leverage intestinal biology to treat metabolic and rare diseases through daily, nutrient-blocking formulations.
